The delay caused by receiving a complete response letter in the end enabled Shire PLC'sXiidra (lifitegrast) to get the best possible indication – to treat both the signs and symptoms of dry eye disease.
The drug cleared FDA July 11 as the first drug for that indication, despite an initial submission with mixed data...